# PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations

> **NCT03609619** · PHASE2 · COMPLETED · sponsor: **Aevi Genomic Medicine, LLC, a Cerecor company** · enrollment: 109 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** AEVI-001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03609619
- **Lead sponsor:** Aevi Genomic Medicine, LLC, a Cerecor company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-17
- **Primary completion:** 2018-11-23
- **Final completion:** 2018-11-30
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03609619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03609619, "PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03609619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*